This is a list of aminorex analogues. Aminorex itself is a stimulant drug with a 5-phenyl-2-amino-oxazoline structure. It was developed in the 1960s as an anorectic, [1] [2] [3] but withdrawn from sale after it was discovered that extended use produced pulmonary hypertension, often followed by heart failure, which resulted in a number of deaths. [4] A designer drug analogue 4-methylaminorex appeared on the illicit market in the late 1980s but did not attract significant popularity due to its steep dose-response curve and tendency to produce seizures. [5] [6] [7] [8] Pemoline , the 4-keto derivative of aminorex, had been discovered several years earlier, [9] and derivatives of this type appeared to be effective stimulants with comparatively low toxicity. [10] [11] Pemoline was sold for around 25 years as a therapy for ADHD and relief of fatigue, before being withdrawn from the market in 2005 because of rare but serious cases of liver failure. [12] [13] [14] [15] More recently in around 2014 another derivative 4,4'-dimethylaminorex started to be sold illicitly, but again swiftly lost popularity due to a spate of fatal overdose cases. [16] [17] [18] A number of related compounds are known, and new derivatives have continued to appear on the designer drug market. [19] [20] [21] [22] [23] [24]
Structure | Common name | Chemical name | CAS number |
---|---|---|---|
Aminorex | 5-phenyl-4,5-dihydro-1,3-oxazol-2-amine | 2207-50-3 | |
Rexamino | 4-phenyl-4,5-dihydro-1,3-oxazol-2-amine | 52883-35-9 | |
4'-Fluoroaminorex (4'-FAR) | 5-(4-fluorophenyl)-4,5-dihydro-1,3-oxazol-2-amine | 2967-77-3 | |
Clominorex | 5-(4-chlorophenyl)-4,5-dihydro-1,3-oxazol-2-amine | 3876-10-6 | |
Fluminorex | 5-[4-(trifluoromethyl)phenyl]-4,5-dihydro-1,3-oxazol-2-amine | 720-76-3 | |
Methylenedioxyaminorex | 5-(3,4-methylenedioxyphenyl)-4,5-dihydro-1,3-oxazol-2-amine | 3865-98-3 | |
2C-B-aminorex (2C-B-AR) | 5-(2,5-dimethoxy-4-bromophenyl)-4,5-dihydro-1,3-oxazol-2-amine | ||
N,N-Dimethylaminorex (N,N-DMAR) | N,N-dimethyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine | 32968-41-5 | |
Pemoline | 2-amino-5-phenyl-1,3-oxazol-4(5H)-one | 2152-34-3 | |
Thozalinone | 2-(dimethylamino)-5-phenyl-1,3-oxazol-4(5H)-one | 655-05-0 | |
Fenozolone | 2-ethylamino-5-phenyl-1,3-oxazol-4-one | 15302-16-6 | |
Cyclazodone | 2-(cyclopropylamino)-5-phenyl-1,3-oxazol-4-one | 14461-91-7 | |
N-Methylcyclazodone | 2-(cyclopropyl(methyl)amino)-5-phenyl-1,3-oxazol-4-one | 14461-92-8 | |
Ephedroxane [25] | (4S,5R)-3,4-dimethyl-5-phenyl-1,3-oxazolidin-2-one | 16251-46-0 | |
3-Methylaminorex | 3-methyl-5-phenyl-2-oxazolidinimine | 75343-73-6 | |
4-Methylaminorex (4-MAR) | 4-methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine | 3568-94-3 | |
4-Ethylaminorex (4-EAR) | 4-ethyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine | 1364933-63-0 | |
4-Isopropylaminorex | 4-isopropyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine | ||
4-Isobutylaminorex | 4-(2-methylpropyl)-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine | ||
4-tert-butylaminorex | 4-(1,1-dimethylethyl)-5-phenyl-4,5-dihydro-1,3-oxazol-2-amine | ||
4,N-Dimethylaminorex (4,N-DMAR) | 4,5-dihydro-N,4-dimethyl-5-phenyl-2-oxazolamine | 2207-49-0 | |
3,4-Dimethylaminorex (3,4-DMAR) | 3,4-dimethyl-5-phenyl-2-oxazolidinimine | 82485-31-2 | |
4,4'-Dimethylaminorex (4,4'-DMAR) | 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine | 1445569-01-6 | |
2'-Fluoro-4-methylaminorex (2F-MAR) | 4-methyl-5-(2-fluorophenyl)-4,5-dihydro-1,3-oxazol-2-amine | ||
3'-Fluoro-4-methylaminorex (3F-MAR) | 4-methyl-5-(3-fluorophenyl)-4,5-dihydro-1,3-oxazol-2-amine | ||
4'-Fluoro-4-methylaminorex (4F-MAR) | 4-methyl-5-(4-fluorophenyl)-4,5-dihydro-1,3-oxazol-2-amine | 1364933-64-1 | |
4'-Chloro-4-methylaminorex (4C-MAR) | 4-methyl-5-(4-chlorophenyl)-4,5-dihydro-1,3-oxazol-2-amine | ||
4'-Bromo-4-methylaminorex (4B-MAR) | 4-methyl-5-(4-bromophenyl)-4,5-dihydro-1,3-oxazol-2-amine | ||
4'-Methoxy-4-methylaminorex (4'-MeO-4-MAR) | 4-methyl-5-(4-methoxyphenyl)-4,5-dihydro-1,3-oxazol-2-amine | 1445570-65-9 | |
3',4',5'-Trimethoxy-4-methylaminorex (TM-4-MAR) | 4-methyl-5-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1,3-oxazol-2-amine | 1445571-92-5 | |
3',4'-Methylenedioxy-4-methylaminorex (MDMAR) | 4-methyl-5-(3,4-methylenedioyphenyl)-4,5-dihydro-1,3-oxazol-2-amine | 1445573-16-9 |
Pemoline, sold under the brand name Cylert among others, is a stimulant medication which has been used in the treatment of attention-deficit hyperactivity disorder (ADHD) and narcolepsy. It has been discontinued in most countries due to rare but serious problems with liver toxicity. The medication was taken by mouth.
4-Methylaminorex is a stimulant drug of the 2-amino-5-aryloxazoline class that was first synthesized in 1960 by McNeil Laboratories. It is also known by its street name "U4Euh" ("Euphoria"). It is banned in many countries as a stimulant.
Aminorex is a weight loss (anorectic) stimulant drug. It was withdrawn from the market after it was found to cause pulmonary hypertension. In the U.S., it is an illegal Schedule I drug, meaning it has high abuse potential, no accepted medical use, and a poor safety profile.
Chlorphentermine is a serotonergic appetite suppressant of the amphetamine family. Developed in 1962, it is the 4-chloro derivative of the better known appetite suppressant phentermine, which is still in current use.
Thozalinone (USAN) is a psychostimulant that has been used as an antidepressant in Europe. It has also been trialed as an anorectic. Thozalinone is described as a "dopaminergic stimulant", and likely acts via inducing the release of dopamine and to a minimal extent norepinephrine; similar to analogue pemoline, it is seemingly devoid of abuse potential unlike common psychostimulants that increase catecholamines.
Fluminorex is a centrally acting sympathomimetic which is related to other drugs such as aminorex and pemoline. It was developed as an appetite suppressant by McNeil Laboratories in the 1950s.
Clominorex is a centrally acting sympathomimetic which is related to other drugs such as aminorex and pemoline. It was developed as an appetite suppressant by McNeil Laboratories in the 1950s.
Cyclazodone is a centrally acting stimulant drug developed by American Cyanamid Company in the 1960s. The drug is related to other drugs such as pemoline and thozalinone. It displayed a favorable therapeutic index and margin of safety in comparison to Pemoline and other N-lower-alkyl-substituted Pemoline derivatives. The patents concluded that Cyclazodone possessed properties efficacious in reducing fatigue and as a potential anorectic. Structural congeners of Pemoline have been described as "excitants with unique properties distinguishing them from the sympathomimetic amines" whilst displaying less stimulatory activity and toxicity compared to amphetamine.
A monoamine releasing agent (MRA), or simply monoamine releaser, is a drug that induces the release of a monoamine neurotransmitter from the presynaptic neuron into the synapse, leading to an increase in the extracellular concentrations of the neurotransmitter. Many drugs induce their effects in the body and/or brain via the release of monoamine neurotransmitters, e.g., trace amines, many substituted amphetamines, and related compounds.
A norepinephrine releasing agent (NRA), also known as an adrenergic releasing agent, is a catecholaminergic type of drug that induces the release of norepinephrine (noradrenaline) and epinephrine (adrenaline) from the pre-synaptic neuron into the synapse. This in turn leads to increased extracellular concentrations of norepinephrine and epinephrine therefore an increase in adrenergic neurotransmission.
Substituted cathinones, which include some stimulants and entactogens, are derivatives of cathinone. They feature a phenethylamine core with an alkyl group attached to the alpha carbon, and a ketone group attached to the beta carbon, along with additional substitutions. Cathinone occurs naturally in the plant khat whose leaves are chewed as a recreational drug.
para-Chloromethamphetamine is a stimulant that is the N-methyl derivative and prodrug of the neurotoxic drug para-chloroamphetamine (4-CA). It has been found to decrease serotonin in rats. Further investigation into the long-term effects of chloroamphetamines discovered that administration of 4-CMA caused a prolonged reduction in the levels of serotonin and the activity of tryptophan hydroxylase in the brain one month after injection of a single dose of the drug.
Substituted phenylmorpholines, or substituted phenmetrazines alternatively, are chemical derivatives of phenylmorpholine or of the psychostimulant drug phenmetrazine. Most such compounds act as releasers of monoamine neurotransmitters, and have stimulant effects. Some also act as agonists at serotonin receptors, and compounds with an N-propyl substitution act as dopamine receptor agonists. A number of derivatives from this class have been investigated for medical applications, such as for use as anorectics or medications for the treatment of ADHD. Some compounds have also become subject to illicit use as designer drugs.
2C-B-aminorex (2C-B-AR) is a recreational designer drug with psychedelic effects. It is a substituted aminorex derivative which was first identified in Sweden in June 2019.
4-Methylphenmetrazine is a recreational designer drug with stimulant effects. It is a substituted phenylmorpholine derivative, closely related to better known drugs such as phenmetrazine and 3-fluorophenmetrazine. It was first identified in Slovenia in 2015, and has been shown to act as a monoamine releaser with some preference for serotonin release.
4'-Fluoro-4-methylaminorex is a recreational designer drug from the substituted aminorex family, with stimulant effects. It was first detected in Slovenia in 2018. It was made illegal in Italy in March 2020.
3',4'-Methylenedioxy-4-methylaminorex (MDMAR) is a recreational designer drug from the substituted aminorex family, with monoamine releasing effects.
4'-Chloro-4-methylaminorex is a recreational designer drug from the substituted aminorex family, with stimulant effects. It has reportedly been sold since around 2021 and was first definitively identified in Austria in January 2022.
2'-Fluoro-4-methylaminorex is a recreational designer drug from the substituted aminorex family, with stimulant effects, first reported in 2018.
4'-Bromo-4-methylaminorex is a designer drug from the substituted aminorex family, first definitively identified in Austria in January 2022. Its pharmacological activity has not been reported, but it is believed to have stimulant effects.